More information: Kotaro Hatta et al, Suvorexant for Reduction of Delirium in Older Adults After Hospitalization, JAMA Network Open (2024). DOI: 10.1001/jamanetworkopen.2024.27691.

Suvorexant, marketed as Belsomra, is the first dual orexin receptor antagonist (DORA) approved for the treatment of insomnia. Developed by Merck & Co., Inc., the drug's journey began in the early ...

Suvorexant is an FDA-approved medication sold under the brand name Belsomra to treat insomnia. ALZHEIMER’S DIAGNOSES EXPECTED TO REACH NEARLY 13 MILLION BY 2050, SAYS NEW REPORT.

Treatment with suvorexant 20 mg led to acutely decreased levels in several Alzheimer’s-related biomarkers. PHILADELPHIA — In cognitively healthy but sleep-poor adults in midlife, ...

Suvorexant was also linked to significantly lower delirium rates than was placebo in a post hoc analysis of patients with hyperactive plus mixed subtypes of dementia (10.9% vs 21.6%; P = .04).

Suvorexant, marketed as Belsomra, is the first dual orexin receptor antagonist (DORA) approved for the treatment of insomnia. Developed by Merck & Co., Inc., the drug's journey began in the early ...

A recent study points specifically to the sleep medication suvorexant as a possible way to help prevent delirium in this vulnerable population. MCKNIGHT’S LONG-TERM CARE NEWS; ...

Suvorexant tablets are available in the doses of 5 mg, 10 mg, 15 mg, 20 mg to be taken by mouth at night time for treating Insomnia or sleeplessness. When it is not to be taken ...

Consistent with expectations, suvorexant showed a trend toward reducing delirium, with only 16.8% of participants exhibiting delirium compared to 26.5% in the placebo group.

New study assesses the efficacy of suvorexant in reducing delirium in older adults. Juntendo University Research Promotion Center. Journal JAMA Network Open DOI 10.1001/jamanetworkopen.2024.27691.